vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Cardlytics, Inc. (CDLX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $50.9M, roughly 1.5× Cardlytics, Inc.). On growth, Bioceres Crop Solutions Corp. posted the faster year-over-year revenue change (-16.8% vs -25.5%). Over the past eight quarters, Bioceres Crop Solutions Corp.'s revenue compounded faster (-8.4% CAGR vs -9.6%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Cardlytics is a leading purchase intelligence and advertising platform that partners with major banks to analyze anonymized consumer transaction data. It delivers targeted, performance-driven ad campaigns for consumer brands, retailers and service providers, helping advertisers reach audiences based on real purchase behavior, with core operations across North America and the United Kingdom.

BIOX vs CDLX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$50.9M
CDLX
Growing faster (revenue YoY)
BIOX
BIOX
+8.6% gap
BIOX
-16.8%
-25.5%
CDLX
Faster 2-yr revenue CAGR
BIOX
BIOX
Annualised
BIOX
-8.4%
-9.6%
CDLX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
CDLX
CDLX
Revenue
$77.6M
$50.9M
Net Profit
$-7.4M
Gross Margin
46.8%
Operating Margin
9.3%
-12.0%
Net Margin
-9.6%
Revenue YoY
-16.8%
-25.5%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CDLX
CDLX
Q4 25
$50.9M
Q3 25
$77.6M
$47.0M
Q2 25
$58.0M
Q1 25
$60.6M
$56.4M
Q4 24
$98.8M
$68.3M
Q3 24
$93.3M
$61.1M
Q2 24
$64.0M
Q1 24
$84.0M
$62.2M
Net Profit
BIOX
BIOX
CDLX
CDLX
Q4 25
Q3 25
$-7.4M
$-72.7M
Q2 25
$-9.3M
Q1 25
$-1.6M
$-13.3M
Q4 24
$605.2K
Q3 24
$-6.2M
$-145.2M
Q2 24
$-4.3M
Q1 24
$9.8M
$-24.3M
Gross Margin
BIOX
BIOX
CDLX
CDLX
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
CDLX
CDLX
Q4 25
-12.0%
Q3 25
9.3%
-146.6%
Q2 25
-22.0%
Q1 25
1.5%
-24.9%
Q4 24
14.5%
-12.2%
Q3 24
2.5%
-243.1%
Q2 24
-24.7%
Q1 24
15.7%
-36.7%
Net Margin
BIOX
BIOX
CDLX
CDLX
Q4 25
Q3 25
-9.6%
-154.7%
Q2 25
-16.0%
Q1 25
-2.6%
-23.5%
Q4 24
0.6%
Q3 24
-6.6%
-237.6%
Q2 24
-6.7%
Q1 24
11.6%
-39.0%
EPS (diluted)
BIOX
BIOX
CDLX
CDLX
Q4 25
$-0.15
Q3 25
$-0.12
$-1.36
Q2 25
$-0.18
Q1 25
$-0.02
$-0.26
Q4 24
$0.00
$-0.36
Q3 24
$-0.10
$-2.90
Q2 24
$-0.09
Q1 24
$0.14
$-0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CDLX
CDLX
Cash + ST InvestmentsLiquidity on hand
$15.5M
$48.7M
Total DebtLower is stronger
$212.6M
Stockholders' EquityBook value
$288.3M
$-6.5M
Total Assets
$734.9M
$285.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CDLX
CDLX
Q4 25
$48.7M
Q3 25
$15.5M
$44.0M
Q2 25
$46.7M
Q1 25
$38.5M
$52.0M
Q4 24
$29.2M
$65.6M
Q3 24
$32.3M
$67.0M
Q2 24
$71.2M
Q1 24
$16.4M
$97.8M
Total Debt
BIOX
BIOX
CDLX
CDLX
Q4 25
$212.6M
Q3 25
$214.6M
Q2 25
$214.3M
Q1 25
$213.9M
Q4 24
$213.6M
Q3 24
$213.2M
Q2 24
$212.9M
Q1 24
$257.9M
Stockholders' Equity
BIOX
BIOX
CDLX
CDLX
Q4 25
$-6.5M
Q3 25
$288.3M
$-4.7M
Q2 25
$58.7M
Q1 25
$345.0M
$64.1M
Q4 24
$346.3M
$70.0M
Q3 24
$346.0M
$69.7M
Q2 24
$210.0M
Q1 24
$348.5M
$199.1M
Total Assets
BIOX
BIOX
CDLX
CDLX
Q4 25
$285.6M
Q3 25
$734.9M
$292.8M
Q2 25
$361.1M
Q1 25
$798.2M
$369.1M
Q4 24
$835.2M
$392.7M
Q3 24
$827.3M
$399.4M
Q2 24
$534.4M
Q1 24
$836.1M
$569.0M
Debt / Equity
BIOX
BIOX
CDLX
CDLX
Q4 25
Q3 25
Q2 25
3.65×
Q1 25
3.34×
Q4 24
3.05×
Q3 24
3.06×
Q2 24
1.01×
Q1 24
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CDLX
CDLX
Operating Cash FlowLast quarter
$14.4M
$13.0M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CDLX
CDLX
Q4 25
$13.0M
Q3 25
$14.4M
$1.8M
Q2 25
$1.2M
Q1 25
$23.3M
$-6.7M
Q4 24
$-5.4M
$3.0M
Q3 24
$5.2M
$1.4M
Q2 24
$4.4M
Q1 24
$-17.4M
$-17.6M
Free Cash Flow
BIOX
BIOX
CDLX
CDLX
Q4 25
$13.0M
Q3 25
$1.7M
Q2 25
$903.0K
Q1 25
$-6.8M
Q4 24
$2.9M
Q3 24
$878.0K
Q2 24
$4.1M
Q1 24
$-18.3M
FCF Margin
BIOX
BIOX
CDLX
CDLX
Q4 25
25.5%
Q3 25
3.7%
Q2 25
1.6%
Q1 25
-12.1%
Q4 24
4.2%
Q3 24
1.4%
Q2 24
6.5%
Q1 24
-29.4%
Capex Intensity
BIOX
BIOX
CDLX
CDLX
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.6%
Q1 25
0.2%
Q4 24
0.2%
Q3 24
0.8%
Q2 24
0.4%
Q1 24
1.0%
Cash Conversion
BIOX
BIOX
CDLX
CDLX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons